Ultragenyx Pharmaceutical earnings were -$559.0M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest RARE earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$133.5M, up 1.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, RARE reported annual earnings of -$606.6M, with -14.2% growth. The next RARE earnings date is Feb 13, 2025.
Ultragenyx Pharmaceutical Earnings Reports & History FAQ
What were Ultragenyx Pharmaceutical's earnings last quarter?
On RARE's earnings call on Invalid Date, Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q3 2024 earnings per share (EPS) of -$1.40, up 37.22% year over year. Total RARE earnings for the quarter were -$133.52 million. In the same quarter last year, Ultragenyx Pharmaceutical's earnings per share (EPS) was -$2.23.
When does Ultragenyx Pharmaceutical report earnings?
The next RARE earnings date is Invalid Date. Add RARE to your watchlist to be reminded of Ultragenyx Pharmaceutical's next earnings date.
What was RARE's earnings growth in the past year?
As of Ultragenyx Pharmaceutical's earnings date in Invalid Date, Ultragenyx Pharmaceutical's earnings has grown year over year. RARE earnings in the past year totalled -$558.99 million.
Is Ultragenyx Pharmaceutical profitable or losing money?
As of the last Ultragenyx Pharmaceutical earnings report, Ultragenyx Pharmaceutical is currently losing money. Ultragenyx Pharmaceutical's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$558.99 million, a 12.01% decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.